626 related articles for article (PubMed ID: 21621716)
1. Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.
Herbst RS; Ansari R; Bustin F; Flynn P; Hart L; Otterson GA; Vlahovic G; Soh CH; O'Connor P; Hainsworth J
Lancet; 2011 May; 377(9780):1846-54. PubMed ID: 21621716
[TBL] [Abstract][Full Text] [Related]
2. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.
Saito H; Fukuhara T; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada M; Yoshimori K; Nakachi I; Gemma A; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara K; Nukiwa T; Morita S; Kobayashi K; Maemondo M
Lancet Oncol; 2019 May; 20(5):625-635. PubMed ID: 30975627
[TBL] [Abstract][Full Text] [Related]
3. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Wu YL; Lee JS; Thongprasert S; Yu CJ; Zhang L; Ladrera G; Srimuninnimit V; Sriuranpong V; Sandoval-Tan J; Zhu Y; Liao M; Zhou C; Pan H; Lee V; Chen YM; Sun Y; Margono B; Fuerte F; Chang GC; Seetalarom K; Wang J; Cheng A; Syahruddin E; Qian X; Ho J; Kurnianda J; Liu HE; Jin K; Truman M; Bara I; Mok T
Lancet Oncol; 2013 Jul; 14(8):777-86. PubMed ID: 23782814
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
[TBL] [Abstract][Full Text] [Related]
5. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial.
Reck M; Kaiser R; Mellemgaard A; Douillard JY; Orlov S; Krzakowski M; von Pawel J; Gottfried M; Bondarenko I; Liao M; Gann CN; Barrueco J; Gaschler-Markefski B; Novello S;
Lancet Oncol; 2014 Feb; 15(2):143-55. PubMed ID: 24411639
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
[TBL] [Abstract][Full Text] [Related]
7. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
[TBL] [Abstract][Full Text] [Related]
8. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer.
Johnson BE; Kabbinavar F; Fehrenbacher L; Hainsworth J; Kasubhai S; Kressel B; Lin CY; Marsland T; Patel T; Polikoff J; Rubin M; White L; Yang JC; Bowden C; Miller V
J Clin Oncol; 2013 Nov; 31(31):3926-34. PubMed ID: 24101054
[TBL] [Abstract][Full Text] [Related]
9. TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Quoix E; Lena H; Losonczy G; Forget F; Chouaid C; Papai Z; Gervais R; Ottensmeier C; Szczesna A; Kazarnowicz A; Beck JT; Westeel V; Felip E; Debieuvre D; Madroszyk A; Adam J; Lacoste G; Tavernaro A; Bastien B; Halluard C; Palanché T; Limacher JM
Lancet Oncol; 2016 Feb; 17(2):212-223. PubMed ID: 26727163
[TBL] [Abstract][Full Text] [Related]
10. First-line erlotinib in patients with advanced non-small-cell lung cancer unsuitable for chemotherapy (TOPICAL): a double-blind, placebo-controlled, phase 3 trial.
Lee SM; Khan I; Upadhyay S; Lewanski C; Falk S; Skailes G; Marshall E; Woll PJ; Hatton M; Lal R; Jones R; Toy E; Chao D; Middleton G; Bulley S; Ngai Y; Rudd R; Hackshaw A; Boshoff C
Lancet Oncol; 2012 Nov; 13(11):1161-70. PubMed ID: 23078958
[TBL] [Abstract][Full Text] [Related]
11. Salvage with erlotinib plus bevacizumab: not in NSCLC.
Sculier JP; Meert AP; Berghmans T
Lancet; 2011 May; 377(9780):1810-2. PubMed ID: 21621709
[No Abstract] [Full Text] [Related]
12. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
[TBL] [Abstract][Full Text] [Related]
13. Design paper: a phase II study of bevacizumab and erlotinib in patients with non-squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous treatment (BEST).
Tanaka S; Sakamori Y; Niimi M; Hazama M; Kim YH; Yanagihara K
Trials; 2011 May; 12():120. PubMed ID: 21569411
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, phase II study of erlotinib with or without sunitinib for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC).
Groen HJ; Socinski MA; Grossi F; Juhasz E; Gridelli C; Baas P; Butts CA; Chmielowska E; Usari T; Selaru P; Harmon C; Williams JA; Gao F; Tye L; Chao RC; Blumenschein GR
Ann Oncol; 2013 Sep; 24(9):2382-9. PubMed ID: 23788751
[TBL] [Abstract][Full Text] [Related]
15. FDA drug approval summary: bevacizumab plus interferon for advanced renal cell carcinoma.
Summers J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2010; 15(1):104-11. PubMed ID: 20061402
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
Herbst RS; O'Neill VJ; Fehrenbacher L; Belani CP; Bonomi PD; Hart L; Melnyk O; Ramies D; Lin M; Sandler A
J Clin Oncol; 2007 Oct; 25(30):4743-50. PubMed ID: 17909199
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial.
Kawashima Y; Fukuhara T; Saito H; Furuya N; Watanabe K; Sugawara S; Iwasawa S; Tsunezuka Y; Yamaguchi O; Okada M; Yoshimori K; Nakachi I; Seike M; Azuma K; Kurimoto F; Tsubata Y; Fujita Y; Nagashima H; Asai G; Watanabe S; Miyazaki M; Hagiwara K; Nukiwa T; Morita S; Kobayashi K; Maemondo M
Lancet Respir Med; 2022 Jan; 10(1):72-82. PubMed ID: 34454653
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study.
Ciuleanu T; Stelmakh L; Cicenas S; Miliauskas S; Grigorescu AC; Hillenbach C; Johannsdottir HK; Klughammer B; Gonzalez EE
Lancet Oncol; 2012 Mar; 13(3):300-8. PubMed ID: 22277837
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial.
Scagliotti GV; Krzakowski M; Szczesna A; Strausz J; Makhson A; Reck M; Wierzbicki RF; Albert I; Thomas M; Miziara JE; Papai ZS; Karaseva N; Thongprasert S; Portulas ED; von Pawel J; Zhang K; Selaru P; Tye L; Chao RC; Govindan R
J Clin Oncol; 2012 Jun; 30(17):2070-8. PubMed ID: 22564989
[TBL] [Abstract][Full Text] [Related]
20. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Soria JC; Wu YL; Nakagawa K; Kim SW; Yang JJ; Ahn MJ; Wang J; Yang JC; Lu Y; Atagi S; Ponce S; Lee DH; Liu Y; Yoh K; Zhou JY; Shi X; Webster A; Jiang H; Mok TS
Lancet Oncol; 2015 Aug; 16(8):990-8. PubMed ID: 26159065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
